Neurology

Three psychiatric pharmacists highlight trends in psychiatric pharmacotherapy that were shared at the AAPP 2026 Annual Meeting.

Neurology pharmacists drive safer medication changes, boost access and financial assistance, and deliver major cost savings through high-impact outpatient pharmacist intervention.

This approval marks the first high-efficacy B-cell depletion therapy approved for pediatric patients 10 years and older.

In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.

The initiatives have intensified discussion surrounding the use of SSRIs, their discontinuation, and broader approaches to mental health care.

New findings presented at the World Congress of Nephrology detail how chronic kidney disease (CKD) drives progressive muscle loss and cognitive decline.

Ambulatory pharmacists can address mental health gaps, tackle stigma and SDOH, and power collaborative care, improving adherence and patient quality of life.

The dextromethorphan-bupropion combination therapy targets NMDA and sigma-1 receptors, offering a first-in-class mechanism distinct from the only other approved agent for this indication.

The approval follows positive results from a phase 3 randomized withdrawal trial.

This new podcast will explore therapies, trends, and clinical decisions shaping neurology from a pharmacist's point of view.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.

A Harvard population health researcher presents findings linking adolescent food insecurity to a cluster of brain health risk factors.

Ecopipam reduces Tourette tic relapse risk by approximately 50% with durable control and no movement-related adverse effects.

Phase 3 data show quarterly cemdisiran injections improve gMG symptoms, either and matches or outperforms all study end points compared to combination therapy.

Cannabidiol may have broader applicability across genetic developmental and epileptic encephalopathies (DEEs).

Cultivating balance and well-being is essential to prevent burnout and foster resilience for future practice.

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

Phase 3 METEOROID shows IL-6 blocker satralizumab cuts MOGAD relapses 68%, with rapid onset and placebo-like safety.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.